Some effects of combination chemotherapy with cis-platinum on renal function in patients with nonseminomatous testicular carcinoma.
Renal function in 24 patients with disseminated nonseminomatous testicular carcinoma treated with combination chemotherapy including cis-platinum was examined prospectively. Renal function was monitored by several determinations of glomerular filtration rate (GFR), effective renal plasma flow (ERPF) and serum creatinine, and beta-2-microglobulin. A reduction in GFR and ERPF was found at the end of the induction chemotherapy and at six weeks thereafter. Median GFR and ERPF decreased both 23% (P less than 0.01). Serum creatinine and beta-2-microglobulin concentrations however did not rise. It is suggested that under the influence of chemotherapy with platinum the production of creatinine and beta-2-microglobulin is decreased rendering their serum levels unsuitable as parameters of renal function.
D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage / Q000494:pharmacology*; D003404:Creatinine / Q000097:blood; D004359:Drug Therapy, Combination; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D007668:Kidney / Q000187:drug effects*; D008297:Male; D011446:Prospective Studies; D012079:Renal Circulation / Q000187:drug effects; D013736:Testicular Neoplasms / Q000188:drug therapy*; D001613:beta 2-Microglobulin / Q000032:analysis
D000970:Antineoplastic Agents; D001613:beta 2-Microglobulin; D003404:Creatinine; D002945:Cisplatin